Benign Prostatic Hyperplasia - BPH Treatment - Enlarged Prostate Treatment
Benign Prostatic Hyperplasia Treatment (BPH Treatment) Overview
Urologix, Inc., based in Minneapolis, Minnesota develops, manufactures and markets minimally invasive urological treatment products. Urologix has developed and offers non-surgical, catheter-based treatments that use proprietary microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix is a leader in less invasive technology for the BPH treatment, with more than 225,0001 patients treated to date.
Urologix' patented Cooled ThermoTherapy™ technology is creating effective2 treatment options for a wide range of patients with BPH. Cooled ThermoTherapy enlarged prostate treatment delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue. This benign prostatic hyperplasia treatment also enhances patient comfort.
Urologix' stock is traded on NASDAQ under the symbol ULGX. The company is focused on product development and expansion of its fast-growing mobile BPH treatment services.
1Data on file at Urologix, Inc.
2Miller, Paul D., et al, Cooled ThermoTherapy for the Treatment of Benign Prostatic Hyperplasia: Durability of Results Obtained with the Targis System, Urology, Vol. 61, No. 6, June 2003.
Milestones
1991
- Urologix® is founded to develop manufacture and market medical devices for the treatment of urological disorders
1997
- Urologix' first product, the Targis® Cooled TUMT System, is approved by the FDA as a safe, durable, minimally invasive urological treatment alternative to drugs and surgery for the treatment of BPH
1999
- Cruise software update including automated urethral feedback introduced
2000
- Urologix purchases the Prostatron® Cooled TUMT System
- Cruise II software update with enhanced rectal temperature feedback preventing unnecessary system shut downs introduced
- Shorter treatment time (28.5 minutes) approved
2002
- Targis Microwave Catheter [Short] introduced
2003
- Targis Microwave Catheter [Long] introduced
- Cooled ThermoCath® (CTC) [Standard] Microwave Catheter receives FDA approval
- Rectal Thermal Unit Plus offered
2005
- Urologix acquires three regional mobile BPH treatment service providers and launched its Urologix Mobile™ Service
- Cooled ThermoCath (CTC) [Long] Microwave Catheter receives FDA approval
2006
- The CoolWave® Control Unit enabling urologists to further customize benign prostatic hyperplasia treatment (BPH treatment) options for individual patients, is approved by the FDA and released to the marketplace
2007
- Developed software upgrade for Targis System
- Began CTC Advance® Microwave Catheter* development
2008
- CTC Advance® Microwave Catheter receives FDA approval
- 5 Year results for Cooled ThermoTherapy™ presented at AUA, Continuing Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH
2009
- 5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Abstract 2122, presented at the 2009 AUA Annual Meeting in Chicago, IL
- Effects of Urethral Temperature on Patient Outcomes for BPH with Cooled High Energy TUMT, Abstract 1944, presented at the 2009 AUA Annual Meeting in Chicago, IL
- CTC Advance® Short Microwave Catheter released to the market to complete CTC Advance Microwave Catheter product line
2010
- Retirement of the Cooled ThermoCath Microwave Catheter product line
- Urologix selected to present at the Geriatric Urological Society Annual Meeting; 'Sexual Function after Cooled High Energy Transurethral Thermotherapy: Results of Patient Clinical Data up to 5 Years Post-Treatment' and 'Intra-Prostatic Temperatures and Necrosis during High Energy Cooled Microwave Treatment'
2011
- 5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH published in the May issue of the Journal of Urology. Authors include L. Mynderse, C. Roehrborn, A. Partin, G. Preminger, and E. Cote.
Board of Directors
Stryker Warren, Jr. |
Chief Executive Officer |
Mitchell Dann |
Chairman of the Board |
Sidney W. Emery, Jr. |
Chief Executive Officer |
Christopher R. Barys |
Corporate Vice President and General Manager |
Patrick D. Spangler |
Chief Financial Officer |
Leadership Team
Stryker Warren, Jr. |
Chief Executive Officer |
Gregory J. Fluet |
Executive Vice President & Chief Operating Officer |
Brian Smrdel |
Chief Financial Officer |
Ralph Cardinal |
Vice President, Research & Development |
Lisa Ackermann |
Vice President, Sales & Marketing |
Jennifer Willner |
Director of Regulatory & Quality |
Charles Lehman |
Director of Operations |
Media Room
Welcome to the Urologix Media Room. This resource is intended for media professionals who are looking to learn more about Urologix and the full range of products we provide for the treatment of symptoms or obstruction due to Benign Prostatic Hyperplasia (BPH).
Downloads
Urologix Fact Sheet
BPH Fact Sheet
Cooled ThermoTherapy Fact Sheet
Prostiva Fact Sheet
Frequently Asked Questions regarding the Exclusive License Agreement
About our Leadership
Recent Press Release
Urologix announces signing of an Exclusive License Agreement for the Prostiva RF (Radio Frequency) Therapy System.
Press Release - September 6, 2011
Image Library
The following images are provided for media professionals as a resource to show Urologix products and services.
CoolWave Control Unit
CTC Advance Microwave Catheter
Urologix Mobile Service Van
Prostiva System
